Five patients with confirmed Fanconi's anemia (FA) and myelodysplasia and/or leukemia underwent stem cell transplantation (SCT) from related donors at KFSHRC. The median age at SCT was 12.6 year (range, 6.2-15 years). Conditioning regimen consisted of cyclophosphamide (CY) 5 mg/kg/day i.v. for 4 days, total body irradiation (TBI) 450 cGy in a single dose. Graft-versus-host disease (GVHD) prophylaxis was with cyclosporine and antithymocyte globulins (ATG). The median time to engraftment (defined as ANCX0.5 Â 10 9 /l) was 16 days (range, 12-26 days). The median time to a self-sustaining platelet count of X20 Â 10 9 /l was 27 days (range, 12-40 days). All patients engrafted. Two patients developed acute GVHD; one of the gut (grade 3) and the other of the skin (grade 1), and one patient developed chronic GVHD of the liver. Four are alive and well with no evidence of the disease; one patient died of bacterial sepsis after controlling her GVHD and clearing her pulmonary aspergillosis and CMV infection. We conclude that the use of low-dose CY plus TBI in patients with FA and MDS/AML undergoing SCT is adequate; the regimen is well tolerated and may be curative for such patients.
/l) was 16 days (range, 12-26 days). The median time to a self-sustaining platelet count of X20 Â 10 9 /l was 27 days (range, 12-40 days). All patients engrafted. Two patients developed acute GVHD; one of the gut (grade 3) and the other of the skin (grade 1), and one patient developed chronic GVHD of the liver. Four are alive and well with no evidence of the disease; one patient died of bacterial sepsis after controlling her GVHD and clearing her pulmonary aspergillosis and CMV infection. We conclude that the use of low-dose CY plus TBI in patients with FA and MDS/AML undergoing SCT is adequate; the regimen is well tolerated and may be curative for such patients. myelodysplasia; total body irradiation; abnormal clone Stem cell transplantation (SCT) has been established as the treatment of choice for marrow failure in patients with Fanconi's anemia (FA), with normalization of the bone marrow defect and excellent survival rates reported with protocols employing reduced doses of cyclophosphamide (CY) with or without radiation therapy. [1] [2] [3] This approach seems, however, less certain when such patients present with myelodysplasia and/or leukemia; preparative regimens have been more intensive, utilizing doses of CY varying from 40 to 200 mg/kg, with total body irradiation (TBI) or busulfan. In this article, we report our experience using low dose of CY (20 mg/kg) with TBI in five such patients.
Patients and methods

Patients
From February 2001 to January 2002, five patients (four girls and one boy) with FA underwent SCT from matched related donors at KFSHRC. Diagnosis of FA was confirmed by documenting increased chromosomal breakage with diepoxybutane (DEB) and/or Mitomycin-C. The median age at SCT was 12.6 years (range, 6.2-15 years); four of the patients presented with anemia and thrombocytopenia, and one patient was referred with acute myeloid leukemia (AML). On bone marrow microscopy, three patients had evidence of myelodysplasia, one had hypoplastic marrow and one had frank AML (M2). Diagnosis of myelodysplasia was based on morphological criteria described by the FAB. These include oval macrocytosis and hypochromic fragments, neutrophil hypogranularity and/or hypolobulation, micromegakaryocytes and hyperlobulated megakayrocytes. 4 The cytogenetic analysis revealed evidence of clonality in four patients; two patients had deletion 5q, one had deletion 1q, and one had monosomy 7 (Table 1) . Four patients received no therapy prior to SCT. The AML patient was treated with chemotherapy; she received Idarubicin i.v. 12 mg/m 2 /day for 3 days, Ara-C 100 mg/m 2 /day as continuous i.v. infusion for 7 days, and 6-Thioguanine p.o. 100 mg/m 2 /day for 7 days. The chemotherapy was repeated after recovering from the first cycle, with Idarubicin given for 2 days and Ara-C and 6-Thioguanine given for 5 days only. Patient was in complete remission (morphologic and cytogenetic) at the time of SCT.
Donors
Four donors were HLA-identical siblings, and one donor was a one HLA-antigen-mismatched sibling (on the A locus); the median age was 5.4 years (range, 1.6-15.9 years). All had normal blood counts and all were tested for increased chromosomal breakage and were found normal. The harvested bone marrows (BM) were not manipulated, and the median CD 34 positive cell count was 5.1 Â 10 6 (range, 3.5-10 Â 10 6 ) per kg recipient body weight.
Preparative regimen
Conditioning was with CY 5 mg/kg once daily i.v. for 4 days (total dose of 20 mg/kg), TBI 450 cGy as a single dose delivered on day À1, and Equine antithymocyte globulins (ATG) 40 mg/kg i.v. on days À6, À4, and À2 (total of 120 mg/kg). GVHD prophylaxis was with cyclosporine at the standard doses. Equine ATG was added at a dose of 20 mg/kg i.v. on days þ 2, þ 4, þ 6, þ 8, þ 10, and þ 12 (total of 120 mg/kg). MESNA was given at a dose of 20 mg/kg i.v. as a 15 min infusion before each dose of CY, then at 3, 6, 9, and 12 h after initiation of each infusion of CY.
Supportive care
All patients were treated in HEPA filtered rooms and were isolated until engraftment. All patients received intravenous immunoglobulins (IVIG) every 2 weeks at a dose of 0.5 g/kg from day À4 until day þ 90 as well as acyclovir 45 mg/kg/day from day À3 to day þ 28. All blood products were leukocyte-filtered and irradiated. Three patients received GCSF. All patients received antifungal prophylaxis with Fluconazole. No prophylactic ganciclovir was given.
Results
Engraftment
Engraftment was defined as an increase in the ANC to X0.5 Â 10 9 /l for three consecutive days. The median time to engraftment was 16 days (range, 12-26 days). The median time to a self-sustaining platelet count of X20 Â 10 9 /l was 27 days (range, 12-40 days). All patients had bone marrow biopsies done on day 28 post SCT that confirmed trilineage engraftment with no evidence of myelodysplasia or leukemia and with normal cytogenetic analysis. Engraftment was further confirmed by chimerism analysis by VNTR (for same sex SCT) or FISH (for opposite sex SCT) on peripheral lymphocytes on day 28; all patients had 100% donor cells.
GVHD
Two patients developed acute GVHD; one developed grade 3 GVHD of the gut, she was treated with steroids and responded favorably, and the other had grade 1 GVHD of the skin that also resolved with steroids. A third patient developed chronic GVHD of the liver; she also developed concomitant pulmonary aspergillosis and CMV infection. Patient was treated; her GVHD got under control, as well as the pulmonary aspergillosis and CMV infection. She, however, died later of bacterial sepsis in a local hospital at 5.3 months post SCT.
Toxicity
Two patients developed mild self-limited veno-occlusive disease of the liver, and none developed hemorrhagic cystitis.
Follow-up
Four of the five patients (80%) are alive with sustained engraftment, at a median follow-up time of 28.5 months (range, 18-30 months).
Discussion
FA belongs to the chromosomal instability syndromes and frequently evolves toward hematopoietic malignancy. The presence of myelodysplasia and/or cytogenetic clonal abnormalities in these patients has long been regarded as a risk factor for evolution to leukemia and hence a predictor of poor outcome. 5, 6 This was shown in a recent observation of 33 patients with FA, which revealed that 48% of the patients had one or more abnormal clones initially or on follow-up. Furthermore, it was demonstrated that the presence of a cytogenetic clone adversely affected This makes allogeneic SCT even a more appealing solution for this particular group of patients. Although allogeneic SCT offers excellent event-free survival for FA patients, 1-3 the presence of MDS represents a therapeutic challenge. Ikushima et al 8 reported a successfully transplanted patient, who was conditioned with CY 100 mg/kg, TBI of 600 cGy, and ATG. In the same article, they summarized the results of 12 patients from different institutions who were conditioned with various protocols, using CY and/or busulfan with or without radiation therapy; six of these patients were alive. Other case reports corroborate that allogeneic SCT may be curative in FA patients who present with myelodysplasia or leukemia. [9] [10] [11] As noted from the review of the literature, no uniform regimen has been used in the different reported patients.
The issue of development of secondary cancers after using a radiation-containing regimen for FA patients remains of concern, 12,13 this risk should however be balanced against the toxicity resulting from the use of higher doses of alkylating agents necessary to ensure adequate eradication of the abnormal clone if radiation in not used. Of note is that factors other than radiation have been implicated in the development of secondary malignancy post SCT in FA patients, such as chronic GVHD, and the use of azathioprine to treat chronic GVHD. 13 Recently, fludarabine has been used as part of nonmyeloablative conditioning regimes facilitating engraftment while sparing the graft-versus-leukemia effect in non-FA patients. Extrapolating from this data, McCloy et al 14 reported one successful allogeneic SCT in a patient with FA in myelodysplastic transformation using a fludarabine-containing regimen. Patient engrafted successfully with minimal toxicity. The approach is appealing, but one case is not enough to justify recommending this regimen, and further experience is needed to validate its efficacy.
Albeit a small series, this report represents the largest group of such patients from one institution treated uniformly. Our results are encouraging, and suggest that SCT using 20 mg/kg of CY in addition to 450-cGy TBI can restore normal hematopoiesis and eradicate the abnormal clone with acceptable toxicity.
